• SM-102: Advanced Engineering of Lipid Nanoparticles for m...

  2025-09-30

  Explore the unique biophysical and predictive engineering aspects of SM-102 in lipid nanoparticles (LNPs) for mRNA delivery. This in-depth article offers new insights into SM-102’s role in optimizing mRNA vaccine development, highlighting emerging computational and experimental approaches.

• SM-102: Design, Biophysical Interactions, and Emerging Ho...

  2025-09-29

  Explore how SM-102 powers lipid nanoparticle (LNP) innovation for mRNA delivery, with a focus on molecular design, biophysical mechanisms, and next-gen applications. This in-depth article uniquely unpacks the molecular underpinnings and optimization strategies for mRNA vaccine development using SM-102.

• SM-102: Molecular Engineering for Next-Gen mRNA Delivery

  2025-09-28

  Explore the molecular engineering of SM-102 in lipid nanoparticles (LNPs) for mRNA delivery and vaccine development. This article uncovers the systems-level design principles, structure–activity relationships, and emerging predictive strategies that set SM-102 apart in mRNA therapeutics.

• SM-102 and LNPs: Data-Driven Design for Next-Gen mRNA The...

  2025-09-27

  Explore how SM-102 empowers rational lipid nanoparticle (LNP) design for mRNA delivery and vaccine development. This article uniquely unpacks data-driven, machine learning-guided strategies to optimize SM-102-based LNPs for advanced mRNA therapeutics.

• SM-102 in Lipid Nanoparticles: Rational Design for Next-G...

  2025-09-26

  Discover how SM-102 enables rational design of lipid nanoparticles (LNPs) for advanced mRNA delivery and vaccine development. This article uniquely explores the intersection of structure-based engineering, ion channel modulation, and machine learning in optimizing SM-102 applications.

• ABT-737 and the Pol II-Mitochondrial Axis: Redefining Apo...

  2025-09-25

  Explore how ABT-737, a potent BCL-2 protein inhibitor, uniquely intersects with RNA Pol II-mediated mitochondrial apoptosis pathways in cancer cells. This in-depth analysis uncovers mechanistic insights and advanced research applications not covered in conventional reviews.

• Recombinant Mouse Sonic Hedgehog: Functional Mechanisms a...

  2025-09-24

  Explore the core mechanisms and advanced research applications of Recombinant Mouse Sonic Hedgehog (SHH) Protein in developmental biology. This article provides a unique, in-depth analysis of SHH-N terminal signaling domain function, experimental validation, and its pivotal role in congenital malformation research.

• ABT-263 (Navitoclax): Unraveling Mitochondrial Apoptosis ...

  2025-09-23

  Explore how ABT-263 (Navitoclax), a potent Bcl-2 family inhibitor, enables rigorous investigation of the mitochondrial apoptosis pathway in the context of RNA Pol II inhibition-induced cell death, offering new perspectives for cancer biology and apoptosis research.

• 2'3'-cGAMP (sodium salt): Advancing STING Agonist Design ...

  2025-09-22

  Explore how 2'3'-cGAMP (sodium salt), a potent STING agonist, is informing next-generation strategies for tumor vasculature normalization and immunotherapy research through its unique activation of the cGAS-STING signaling pathway.

• Propidium Iodide: Advanced Applications in Immune Cell Ap...

  2025-09-19

  This article explores the advanced scientific uses of Propidium iodide as a PI fluorescent DNA stain for apoptosis detection and cell viability assays, focusing on immune cell research and recent findings in preeclampsia models. It highlights best practices, technical considerations, and novel interpretations for rigorous flow cytometry DNA staining.

• Bufuralol Hydrochloride in Advanced β-Adrenergic Pharmaco...

  2025-09-18

  Explore the unique applications of Bufuralol hydrochloride as a non-selective β-adrenergic receptor antagonist in modern cardiovascular pharmacology research. This article highlights its mechanistic roles, utility in β-adrenergic modulation studies, and integration with emerging hiPSC-derived organoid models.

• MD was the recipient of the Intergroupe Francophone de Canc

  2025-03-03

  

  MD was the recipient of the Intergroupe Francophone de Cancérologie Thoracique (IFCT) Alain Depierre Grant in 2014. JP was the recipient of the ARISTOT (Association de Recherche, d’Information Scientifique et Thérapeutique en Oncologie Thoracique) grant in 2016. Conflicts of interest statement

• Introduction Aldose reductase ALR is the

  2025-03-03

  

  Introduction Aldose reductase (ALR2) is the first enzyme of the polyol pathway that catalyzes the reduction of glucose to sorbitol utilizing NADPH as a cofactor. The intracellular accumulation of sorbitol, due to increased aldose reductase activity at high blood glucose levels, such as those occurr

• br Author contributions br Funding This

  2025-03-03

  

  Author contributions Funding This work was supported by the Czech Science Foundation, project no. 14-16220S. Additional support was provided by NIH R01CA117907 grant awarded to J.M.E. Conflict of interest Introduction The dioxin-like family includes polyhalogenated aromatic hydrocarbons

• Cancers that responded to immune checkpoint inhibitors

  2025-03-03

  

  Cancers that responded to immune checkpoint inhibitors were shown to present a type I interferon (IFN) signature in the TME 33, 34. Type I IFNs positively regulate the expression of tumor antigens and their crosspresentation by DCs to tumoricidal CTLs. Furthermore, CD8+ T cell develops full effector

15764 records 1/1051 page Next 12345 下5页 Last page